DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).

How it works

Dextrose provides a source of carbohydrates for metabolism, while Lactated Ringer's solution replaces extracellular fluid and electrolytes. Lactate is converted to bicarbonate in the liver, providing buffer.

What the body does with it

Metabolism	Dextrose undergoes glycolysis and oxidative phosphorylation. Lactate is metabolized primarily in the liver to bicarbonate via gluconeogenesis and the Cori cycle.
Excretion	Lactate is metabolized to bicarbonate in the liver (80%) and kidneys (20%); dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle; water is excreted renally (100%), electrolytes (Na+, K+, Ca2+, Cl-) are primarily renally eliminated with minimal fecal loss (<2%).
Half-life	Dextrose: 1-2 hours (intracellular utilization); lactate: 10-20 minutes (hepatic metabolism); water and electrolytes: distribution half-life ~20-30 minutes, elimination half-life determined by renal function (normal ~2-4 hours).
Protein binding	Dextrose: negligible; lactate: <10% (albumin); electrolytes: minimally protein-bound (<5%).
Volume of Distribution	Dextrose: 0.2-0.3 L/kg (extracellular fluid); lactate: 0.4-0.5 L/kg (total body water); water: 0.6 L/kg (total body water); electrolytes distribute according to physiological compartments (Na+ 0.25 L/kg, K+ 4 L/kg (intracellular)).
Bioavailability	IV: 100%
Onset of Action	IV: Immediate expansion of intravascular volume and glucose availability within seconds to minutes.
Duration of Action	IV: Caloric and hydration effects persist for 2-4 hours; buffer effect (lactate conversion to bicarbonate) lasts 1-2 hours.

Classification & Brands

Dosing & administration

Intravenous infusion, dose depends on fluid and caloric needs; typical adult dose is 30-40 mL/kg/day, not to exceed 100 mL/hour in normovolemic patients without cardiac impairment.

Dosage form	INJECTABLE
Renal impairment	For GFR 30-50 mL/min: use with caution and monitor fluid status; GFR <30 mL/min: avoid due to risk of hyperkalemia and fluid overload from lactate and potassium content.
Liver impairment	Child-Pugh Class B: use with caution, monitor lactate levels and fluid balance; Class C: avoid due to impaired lactate metabolism.
Pediatric use	Dose based on weight: 5-10 mL/kg/dose IV, frequency adjusted to maintenance needs (e.g., 100-150 mL/kg/day for infants), not to exceed 0.5-1 g/kg/hour of dextrose.
Geriatric use	Start at lower end of dosing range (20-30 mL/kg/day), monitor for fluid overload and electrolyte imbalances due to decreased renal function and cardiac reserve.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).

Breastfeeding	Excreted into breast milk in insignificant amounts; no adverse effects expected in infants. M/P ratio not determined due to endogenous nature.
Teratogenic Risk	No known teratogenic risk at therapeutic doses; dextrose and lactated Ringer's are standard maintenance fluids. However, use in hyperglycemia or electrolyte imbalances may pose indirect risks. No trimester-specific adverse fetal effects reported.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Not for use in newborns, especially preterm infants, due to risk of aluminum toxicity from prolonged parenteral administration.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperglycemia","Hyperlactatemia","Severe metabolic acidosis","Hypersensitivity to any component","Patients with increased lactate levels (e.g., severe hepatic failure)"]

Clinical Precautions

Precautions

["Monitor serum glucose, electrolytes, and acid-base balance","Risk of hyperglycemia in diabetic patients","Risk of fluid overload in patients with cardiac or renal impairment","Avoid in patients with lactic acidosis"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).

How it works

What the body does with it

Metabolism	Dextrose undergoes glycolysis and oxidative phosphorylation. Lactate is metabolized primarily in the liver to bicarbonate via gluconeogenesis and the Cori cycle.
Excretion	Lactate is metabolized to bicarbonate in the liver (80%) and kidneys (20%); dextrose is metabolized to CO2 and water via glycolysis and the Krebs cycle; water is excreted renally (100%), electrolytes (Na+, K+, Ca2+, Cl-) are primarily renally eliminated with minimal fecal loss (<2%).
Half-life	Dextrose: 1-2 hours (intracellular utilization); lactate: 10-20 minutes (hepatic metabolism); water and electrolytes: distribution half-life ~20-30 minutes, elimination half-life determined by renal function (normal ~2-4 hours).
Protein binding	Dextrose: negligible; lactate: <10% (albumin); electrolytes: minimally protein-bound (<5%).
Volume of Distribution	Dextrose: 0.2-0.3 L/kg (extracellular fluid); lactate: 0.4-0.5 L/kg (total body water); water: 0.6 L/kg (total body water); electrolytes distribute according to physiological compartments (Na+ 0.25 L/kg, K+ 4 L/kg (intracellular)).
Bioavailability	IV: 100%
Onset of Action	IV: Immediate expansion of intravascular volume and glucose availability within seconds to minutes.
Duration of Action	IV: Caloric and hydration effects persist for 2-4 hours; buffer effect (lactate conversion to bicarbonate) lasts 1-2 hours.

Classification & Brands

Dosing & administration

Intravenous infusion, dose depends on fluid and caloric needs; typical adult dose is 30-40 mL/kg/day, not to exceed 100 mL/hour in normovolemic patients without cardiac impairment.

Dosage form	INJECTABLE
Renal impairment	For GFR 30-50 mL/min: use with caution and monitor fluid status; GFR <30 mL/min: avoid due to risk of hyperkalemia and fluid overload from lactate and potassium content.
Liver impairment	Child-Pugh Class B: use with caution, monitor lactate levels and fluid balance; Class C: avoid due to impaired lactate metabolism.
Pediatric use	Dose based on weight: 5-10 mL/kg/dose IV, frequency adjusted to maintenance needs (e.g., 100-150 mL/kg/day for infants), not to exceed 0.5-1 g/kg/hour of dextrose.
Geriatric use	Start at lower end of dosing range (20-30 mL/kg/day), monitor for fluid overload and electrolyte imbalances due to decreased renal function and cardiac reserve.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER (DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER).

Breastfeeding	Excreted into breast milk in insignificant amounts; no adverse effects expected in infants. M/P ratio not determined due to endogenous nature.
Teratogenic Risk	No known teratogenic risk at therapeutic doses; dextrose and lactated Ringer's are standard maintenance fluids. However, use in hyperglycemia or electrolyte imbalances may pose indirect risks. No trimester-specific adverse fetal effects reported.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

Not for use in newborns, especially preterm infants, due to risk of aluminum toxicity from prolonged parenteral administration.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hyperglycemia","Hyperlactatemia","Severe metabolic acidosis","Hypersensitivity to any component","Patients with increased lactate levels (e.g., severe hepatic failure)"]